Testosterone AndroGel Lawsuits

A Texas man’s testosterone gel lawsuit is one of many testosterone treatment lawsuits filed against AbbVie and Abbott Laboratories regarding the low-testosterone (low-T) treatment AndroGel.

David Lyon alleges in his lawsuit that he suffered a myocardial infarction (heart attack) and that the companies misled consumers to believe the product is safe.

Lyon stated that prior to the AndroGel treatment he was active, despite his age of 72. His lawsuit states that when he was prescribed testosterone replacement therapy in January 2005 for low testosterone, he was healthy and had no prior history of cardiac issues.

In November 2005, Lyon allegedly suffered a heart attack that severely impacted his personal and profession life. Like most of the other AndroGel lawsuits contend, Lyon accuses AbbVie of convincing men that they are suffering from a fictional disease called “Low-T” by stating that the normal side effects of aging are actually indications of a far more serious condition, such as hypogonadism.

Lyon is one of the many men who allege they have suffered cardiac complications from using AndroGel and his testosterone gel lawsuit accuses AbbVie of negligence and other product liability issues.

There have been increasing reports of patients suffering side effects including heart attack, deep vein thrombosis, pulmonary embolism and stroke. In January, the FDA announced a review of testosterone treatment products due to reports of problems.

A study published in the November 2013 Journal of the American Medical Association (JAMA) suggested that the side effects of testosterone treatment drugs would likely increase the risk of heart attack, stroke and death among older men with certain heart problems. The medical journal PLOSOne in January reported that testosterone treatment drugs may double the risk of heart attack for younger men with heart disease and men over the age of 65, whether or not they had heart conditions.

Earlier this month, a motion was filed calling for all testosterone drug lawsuits to be centralized as part of a multidistrict litigation, to reduce duplicative discovery and avoid conflicting rulings from different judges. The U.S. Judicial Panel on Multidistrict Litigation heard oral arguments over the AndroGel lawsuit consolidation. A ruling is expected soon and we will keep you posted.

For more information, contact one of our Gacovino Lake attorneys at 1-800-246-HURT (4878).

Related Posts